232 related articles for article (PubMed ID: 18000316)
1. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Lynd LD; Goeree R; Crowther MA; O'Brien BJ
Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 18000316
[TBL] [Abstract][Full Text] [Related]
2. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Lynd LD; Goeree R; Crowther MA; O'Brien BJ
Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 17652767
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma.
Devlin JW; Petitta A; Shepard AD; Obeid FN
Pharmacotherapy; 1998; 18(6):1335-42. PubMed ID: 9855335
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
McGarry LJ; Thompson D; Weinstein MC; Goldhaber SZ
Am J Manag Care; 2004 Sep; 10(9):632-42. PubMed ID: 15515996
[TBL] [Abstract][Full Text] [Related]
5. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.
O'Brien BJ; Anderson DR; Goeree R
CMAJ; 1994 Apr; 150(7):1083-90. PubMed ID: 8137188
[TBL] [Abstract][Full Text] [Related]
7. Deep venous thrombosis prophylaxis in trauma: cost analysis.
Wade WE; Chisholm MA
Blood Coagul Fibrinolysis; 2000 Jan; 11(1):101-6. PubMed ID: 10691104
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
Menzin J; Colditz GA; Regan MM; Richner RE; Oster G
Arch Intern Med; 1995 Apr; 155(7):757-64. PubMed ID: 7695464
[TBL] [Abstract][Full Text] [Related]
9. Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients.
Arnold JD; Dart BW; Barker DE; Maxwell RA; Burkholder HC; Mejia VA; Smith PW; Longley JM
Am Surg; 2010 Jun; 76(6):563-70. PubMed ID: 20583509
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
[TBL] [Abstract][Full Text] [Related]
11. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin.
Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R
Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of enoxaparin as postdischarge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery.
Davies LM; Richardson GA; Cohen AT
Value Health; 2000; 3(6):397-406. PubMed ID: 16464199
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
Deitelzweig SB; Becker R; Lin J; Benner J
Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
de Lissovoy G; Subedi P
Am J Manag Care; 2002 Dec; 8(12):1082-8. PubMed ID: 12500884
[TBL] [Abstract][Full Text] [Related]
16. Enoxaparin for thromboprophylaxis after major trauma: potential cost implications.
Shorr AF; Ramage AS
Crit Care Med; 2001 Sep; 29(9):1659-65. PubMed ID: 11546959
[TBL] [Abstract][Full Text] [Related]
17. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement.
Marchetti M; Liberato NL; Ruperto N; Barosi G
Haematologica; 1999 Aug; 84(8):730-7. PubMed ID: 10458700
[TBL] [Abstract][Full Text] [Related]
18. Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice.
Menown I; Montalescot G; Pal N; Fidler C; Orme M; Gillard S
Adv Ther; 2010 Mar; 27(3):181-91. PubMed ID: 20422473
[TBL] [Abstract][Full Text] [Related]
19. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis.
Shorr AF; Jackson WL; Weiss BM; Moores LK
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):309-16. PubMed ID: 17473570
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients--a pharmacoeconomic analysis.
Wilbur K; Lynd LD; Sadatsafavi M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):454-65. PubMed ID: 20699258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
